¡¡¡¡ÖÐÐÂÍø¸£½¨ÐÂÎÅ12ÔÂ2ÈÕµç (ÐíìÇæÃ »ÆÇÕ)½üÈÕ£¬2024¸£½¨ÖÐÎ÷Ò½½áºÏÑо¿ÔºÑ§ÊõÄê»áôßÖйúÖÐÎ÷Ò½½áºÏѧ»á¿ÆÑÐÔºËù¹¤×÷ίԱ»áѧÊõÄê»áÔÚ¸£½¨ÖÐÒ½Ò©´óѧ¾ÙÐУ¬¸£½¨Ê¡ÖÐÎ÷Ò½½áºÏѧ»áѧÊõÄê»áͬÆÚ¾Ù°ì¡£

¡¡¡¡»áÒéÓɸ£½¨ÖÐÒ½Ò©´óѧ¡¢¸£½¨ÖÐÎ÷Ò½½áºÏÑо¿Ôº¡¢ÖйúÖÐÎ÷Ò½½áºÏѧ»á¡¢¸£½¨Ê¡ÖÐÎ÷Ò½½áºÏѧ»á¹²Í¬Ö÷°ì£¬À´×Ôº£ÄÚÍâÖÐÎ÷Ò½½áºÏÁìÓòµÄר¼ÒѧÕß¡¢Ê¦Éú´ú±í¹²400ÓàÈ˲μӻáÒé¡£
¡¡¡¡»áÒéÖ÷Ìâ¾Û½¹ÓÚ¡°¿ª·Å°üÈÝ£¬´Ù½øÖÐÎ÷Ò½½áºÏ·¢Õ¹¡±£¬º¸Ç´ó»á±¨¸æ¡¢ÐÄÄÔѪ¹Ü²¡ÂÛ̳¡¢Ö×ÁöÓë´úлÂÛ̳¡¢¸£½¨Ê¡ÖÐҽҩѧ»áÖÐÒ½¹ÇÉË·Ö»áѧÊõÄê»áר¼ÒÂÛ̳¡¢½éÈëҽѧ·Ö»áÇàÄêѧÊõÂÛ̳¡¢ÇàÄêÂÛ̳ÒÔ¼°Ñо¿ÉúÂÛ̳µÈ»·½Ú¡£
¡¡¡¡ÔÚ´ó»áÖ÷Ö¼±¨¸æ»·½Ú£¬¸£½¨ÖÐÎ÷Ò½½áºÏÑо¿Ôº¸±Ôº³¤ñÒ½£·æ»ã±¨ÁËÖÐÎ÷Ò½½áºÏÑо¿ÔºÄê¶È¹¤×÷£»Ïã¸Û½þ»á´óѧ¸±Ð£³¤¡¢Å·ÖÞ¿ÆÑ§ÔºÔºÊ¿ÂÀ°®Æ½½ÌÊÚÎ§ÈÆ¡¶ÖÐÎ÷Ò½½áºÏҽѧÓëδÀ´Ò½Ñ§·¢Õ¹¡··¢±íÁËÉî¿Ì¼û½â£»¸ÊËàÖÐÒ½Ò©´óѧ¸±Ð£³¤ÁõÓÀçù½ÌÊÚÔò¾Í¡¶»ùÓÚ¡°ÌåÓû¯¡±±æÖÎÌåϵƢÔà·½·ÀÖλ¯ÁÆÒ©ÎïÓÕ·¢³¦Ä¤Ñ×µÄ×÷ÓÃÑо¿¡·½øÐÐÁËÉîÈë²ûÊö£»¸£½¨ÖÐÒ½Ò©´óѧÖìΰ¶«½ÌÊÚÒÔ¡¶Inhibition of a novel Dickkopf-1-LDL receptor¨Crelated proteins5 and6 axis prevents diabetic cardiomyopathy in mice¡·ÎªÌ⣬·ÖÏíÁËÆä×îÐÂÑо¿³É¹û¡£
¡¡¡¡Óë»áר¼ÒÎ§ÈÆÖÐÎ÷Ò½½áºÏµÄ´«³Ð¡¢´´ÐÂÓë·¢Õ¹ÀíÄî¡¢·½·¨¼°Í¾¾¶Õ¹¿ªÁËÉîÈëµÄѧÊõ½»Á÷ɳÁú£¬ÏÖ³¡·ÕΧ³äÂúÁËѧÊõÊÓÒ°ÍØÕ¹ºóµÄ˼άÅöײ¡£
¡¡¡¡ÐÄÄÔѪ¹Ü²¡ÂÛ̳»ã¾ÛÁË7λÐÄÄÔѪ¹ÜÑо¿ÁìÓòµÄȨÍþר¼Ò£¬ËûÃÇ·Ö±ð¾ÍÖÐÎ÷Ò½½áºÏÐÄѪ¹Ü²¡µÄÑо¿Óë·¢Õ¹×÷Á˾«²Ê±¨¸æ£¬ÎªÓë»áÕß´øÀ´Á˱¦¹óµÄѧÊõÆôʾ¡£

¡¡¡¡Ö×ÁöÓë´úлÂÛ̳ÑûÇëÁË7λÖ×ÁöÓë´úлÑо¿ÁìÓòµÄÖªÃûר¼Ò£¬¹²Í¬ÑÐÌÖÖ×ÁöÓë´úлÑо¿µÄ×îÐÂÀíÂÛ½øÕ¹¡¢ÁÙ´²Êµ¼ùºÍ¿ÆÑгɹû¡£
¡¡¡¡¸£½¨Ê¡ÖÐҽҩѧ»áÖÐÒ½¹ÇÉË·Ö»áѧÊõÄê»áר¼ÒÂÛ̳ÑûÇëÁË3λÖÐÒ½¹ÇÉË¿ÆÑо¿ÁìÓòµÄ½Ü³öר¼Ò£¬¾ÍÖÐÒ½¹ÇÉ˵Ä×îÐÂÀíÂÛ½øÕ¹¡¢ÁÙ´²Êµ¼ùºÍ¿ÆÑгɹû½øÐÐÁËÉîÈëÑÐÌÖ¡£
¡¡¡¡½éÈëҽѧ·Ö»áÇàÄêѧÊõÂÛ̳ÉÏ£¬¸£½¨Ê¡ÖÐÎ÷Ò½½áºÏѧ»á»á³¤Åí¾ü½ÌÊÚÒÔÆäÉîºñµÄѧÊõµ×ÔÌ£¬×öÁË¡°ÖÐÎ÷Ò½½áºÏÖÎÁƸßѪѹÁìÓòµÄ´«³ÐÓ봴С±µÄÖ÷Ö¼±¨¸æ¡£À´×Ôȫʡ¸÷µØÊС¢¸÷Ò½ÁÆ»ú¹¹ÖÐÎ÷Ò½½áºÏ¼°½éÈëҽѧµÄ9λÇàÄêר¼ÒѧÕßÃÇ£¬Î§ÈÆÖÐÎ÷Ò½½áºÏ¼°½éÈëҽѧµÄÇ°ÑØÑо¿£¬Õ¹ÏÖÁËÒ»³¡Ë¼ÏëÅöײÓëҽѧ´´ÐµÄѧÊõÊ¢Ñç¡£
¡¡¡¡Ñо¿ÉúÂÛ̳ͬÑù¾«²Ê·×³Ê£¬¹²ÑûÇëÁË11λÖÐÎ÷Ò½½áºÏÁìÓòÑо¿Éú½øÐÐÁËÖ÷Ìⱨ¸æ¡£
¡¡¡¡Ö÷°ì·½Ö¸³ö£¬±¾´ÎÄê»á²»½ö»ã¾ÛÁ˺£ÄÚÍâÖÚ¶àÖªÃûר¼ÒѧÕߣ¬¹²Í¬Ì½ÌÖÖÐÎ÷Ò½½áºÏµÄ´«³Ð¡¢´´ÐÂÓë·¢Õ¹Ö®µÀ£¬»¹Í¨¹ý¶à¸öרҵÂÛ̳³ä·ÖչʾÁËÖÐÎ÷Ò½½áºÏÁìÓòµÄ×îÐÂÑо¿³É¹ûºÍÇ°ÑØ¶¯Ì¬¡£(Íê)